deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00431912

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma

Sponsor: Valerio Therapeutics

Conditions Cutaneous T-cell Lymphoma
Interventions APO866
Updated 7 times since 2017 Last updated: Jul 7, 2015 Started: Feb 28, 2007 Primary completion: Jan 31, 2011 Completion: Sep 30, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00431912, this PHASE2 trial focuses on Cutaneous T-cell Lymphoma and remains completed. Sponsored by Valerio Therapeutics, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jan 2024 · 36 months · monthly snapshotCompleted~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 9 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jan 2024 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Valerio Therapeutics
Data source: Valerio Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations